Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H-ferritin siRNA is a small interfering RNA therapeutic candidate designed to silence the expression of the ferritin heavy chain (FTH1) gene. Ferritin is primarily known as an intracellular iron storage protein, but it also localizes to the nuclei of tumor cells, where it protects DNA from oxidative damage and facilitates transcription. By knocking down H-ferritin levels, this siRNA disrupts iron homeostasis and increases the sensitivity of cancer cells, such as glioma, to DNA-alkylating chemotherapeutic agents like carmustine (BCNU). Preclinical studies have demonstrated that delivery via cationic liposomes can significantly reduce the effective dose of chemotherapy required for tumor suppression and increase apoptosis in vitro and in vivo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on H-ferritin siRNA.